Q-omics provides the consensus-scored MT-TM profile across patient tissues and cancer cell-line models. MT-TM expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MT-TM is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, MT-TM RNA expression shows 11,357 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where MT-TM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-TM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-TM survival associations across molecular data types. MT-TM RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-TM RNA expression–survival associations across cancer types. High MT-TM expression shows unfavorable associations in UVM, KIRC, UCEC, MESO and PRAD, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MT-TM RNA expression.
This table summarizes MT-TM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MT-TM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-TM shows lower tumor expression in HNSC, KIRC and KIRP and higher tumor expression in COAD, LIHC and LUAD. The COAD box plot shows higher MT-TM RNA expression in tumor versus normal tissue (log2 FC = +2.740, t-test p < 0.001).
This table shows molecular features associated with MT-TM in patient tissues and cancer cell lines. In patient samples, MT-TM shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
